SCHOTT appoints Supervisory Board of SCHOTT Pharma AG & Co. KGaA
Friday, April 28, 2023, Mainz, Germany
- New corporate body with shareholders’ representatives active until 2026
- The Supervisory Board with Peter Goldschmidt as elected Chairman comprises long-standing know-how in the pharma industry and management expertise
With this move, SCHOTT is taking steps to ensure sustainable value creation for its SCHOTT Pharma business in line with international standards. SCHOTT Pharma AG & Co. KGaA is a pioneer in drug containment and delivery solutions for injectable drugs and has achieved a strong profitability, outperforming market growth rates in recent years according to its own estimates.
“SCHOTT Pharma is looking at exciting milestones ahead. The establishment of a Supervisory Board with members from outside the SCHOTT Group is a further important step towards SCHOTT Pharma’s capital market readiness. The newly appointed members have an excellent track record to govern the Management Team in taking full advantage of tremendous opportunities,” said Dr. Frank Heinricht, CEO of SCHOTT AG. The mandates are effective until the Annual General Meeting for the fiscal year ending 30 September 2026.
“Speaking on behalf of the Supervisory Board, we’re looking forward to contributing our expertise to SCHOTT Pharma’s exciting journey,” said Chairman Peter Goldschmidt. “SCHOTT Pharma has a strong track record and inspiring innovations in its pipeline, which hold the potential to further advance the pharma industry.”
Head of Corporate Communications